Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01213524 · ClinicalTrials.gov registry record · Phase 2
Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia
A Phase 2 study, sponsored by Brown University.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT01213524 is a Phase 2 study that has completed, run by Brown University. The registered enrollment target is 75 participants.
The verdict
NCT01213524, a Phase 2 study, has completed, sponsored by Brown University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
The objective of this study is to investigate the relative contributions of nicotine replacement and sensorimotor replacement (i.e., smoking denicotinized cigarettes) on abstinence-induced smoking urges, withdrawal-related negative affect, psychiatric symptoms, cognitive task performance and 90-min ad libitum usual-brand smoking behavior in smokers with schizophrenia and non-psychiatric smokers.
Interventions
- BEHAVIORAL sensorimotor replacement
- DRUG 42 mg transdermal nicotine replacement
- DRUG Placebo transdermal nicotine
- OTHER usual brand smoking
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2005-09 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01213524
The ClinicalTrials.gov registry entry for NCT01213524 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which sensorimotor replacement is the first listed.
NCT01213524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01213524 about?
NCT01213524 is a clinical study titled "Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia". The objective of this study is to investigate the relative contributions of nicotine replacement and sensorimotor replacement (i.e., smoking denicotinized cigarettes) on abstinence-induced smoking urges, withdrawal-related negative affect, psychiatric symptoms, cognitive task performance and 90-min ...
What is the current status of trial NCT01213524?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2005-09. Estimated completion is 2011-03.
What interventions are being tested in trial NCT01213524?
The interventions under investigation include: sensorimotor replacement (BEHAVIORAL), 42 mg transdermal nicotine replacement (DRUG), Placebo transdermal nicotine (DRUG), usual brand smoking (OTHER).
Who is sponsoring clinical trial NCT01213524?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.